Short Interest in Henry Schein, Inc. (NASDAQ:HSIC) Increases By 28.9%

Henry Schein, Inc. (NASDAQ:HSIC) was the recipient of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 5,374,661 shares, a growth of 28.9% from the February 26th total of 4,168,764 shares. Approximately 4.7% of the company’s stock are short sold. Based on an average daily volume of 1,379,464 shares, the short-interest ratio is currently 3.9 days.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Barclays began coverage on shares of Henry Schein in a report on Monday, December 8th. They issued an “overweight” rating and a $86.00 price target on the stock. Wall Street Zen downgraded shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Barrington Research set a $97.00 target price on shares of Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Robert W. Baird set a $100.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Monday, February 23rd. Finally, Leerink Partners reiterated a “market perform” rating on shares of Henry Schein in a research note on Monday, March 9th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Henry Schein has an average rating of “Hold” and an average target price of $85.58.

Insider Transactions at Henry Schein

In other Henry Schein news, CEO Thomas C. Popeck sold 1,355 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $72.79, for a total transaction of $98,630.45. Following the completion of the sale, the chief executive officer owned 86,182 shares in the company, valued at $6,273,187.78. This trade represents a 1.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kurt P. Kuehn sold 2,844 shares of Henry Schein stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total value of $224,562.24. Following the sale, the director owned 15,420 shares in the company, valued at $1,217,563.20. This represents a 15.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 105,911 shares of company stock valued at $8,574,982 in the last three months. 1.08% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Henry Schein

Institutional investors have recently modified their holdings of the business. Hsbc Holdings PLC lifted its holdings in Henry Schein by 2.5% in the fourth quarter. Hsbc Holdings PLC now owns 123,550 shares of the company’s stock worth $9,353,000 after acquiring an additional 3,014 shares during the last quarter. Reflection Asset Management bought a new position in shares of Henry Schein during the fourth quarter valued at approximately $516,000. Compound Planning Inc. acquired a new stake in shares of Henry Schein during the 4th quarter worth approximately $275,000. Corient Private Wealth LLC lifted its holdings in shares of Henry Schein by 5.4% in the 4th quarter. Corient Private Wealth LLC now owns 37,019 shares of the company’s stock worth $2,798,000 after purchasing an additional 1,906 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV lifted its holdings in shares of Henry Schein by 7.8% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,318 shares of the company’s stock worth $326,000 after purchasing an additional 312 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Performance

HSIC traded down $1.61 during trading hours on Friday, hitting $72.10. 982,731 shares of the stock were exchanged, compared to its average volume of 1,305,034. The stock has a 50-day simple moving average of $77.37 and a 200-day simple moving average of $73.22. Henry Schein has a 12 month low of $60.56 and a 12 month high of $89.29. The stock has a market cap of $8.27 billion, a price-to-earnings ratio of 22.05, a price-to-earnings-growth ratio of 2.13 and a beta of 0.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.76.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The firm had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter in the previous year, the company posted $1.19 earnings per share. The firm’s revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Analysts anticipate that Henry Schein will post 4.74 earnings per share for the current year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.